Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro

PHILADELPHIA, May 5, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon® N, significantly inhibited the replication...
April 08, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces New Publication Enlarges the Understanding of Ampligen(R) Safety Profile Across Diverse Animal Species and Focuses on the Unique TLR-3 Receptor/Ampligen(R) Interaction

PHILADELPHIA, April 8, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced today the peer-reviewed publication titled "Discordant Biological and...
March 24, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma, Inc. Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference

PHILADELPHIA, March 24, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) participated in the 11th Biennial International Research and Clinical Conference held in San Francisco,...
March 19, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference

PHILADELPHIA, March 19, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) will participate in the 11th Biennial International Research and Clinical Conference to be held in San...
March 10, 2014 11:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen(R) to Treat Chronic Fatigue Syndrome (CFS) in Three Additional Latin America Countries

PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it and its partner in Latin America, GP Pharm, are planning...
March 10, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees

PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"or "Hemispherx"), announced that after more than a week in trial, a federal jury in Atlanta...
February 24, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Publishes Full National Press Club Presentation on Corporate Website

PHILADELPHIA, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the full text of the Hemispherx presentation given at the National Press Club (NPC) Conference...
February 04, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Summarizes Clinical Results Presented in Washington, DC on January 30, 2014 in Conjunction with the American Society for Microbiology (ASM) Biodefense Conference Aimed at Developing a Universal Influenza Vaccine to Prevent Pandemic Influenza Threat

PHILADELPHIA, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), presented a summary of the results of its Phase I/II study from the poster...
January 28, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

A Clinical Update on the Search for a Universal Flu Vaccine: Presentation in Washington, DC on January 30, 2014 in Conjunction With the American Society for Microbiology (ASM) Biodefense Conference

PHILADELPHIA, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the ASM Biodefense Meeting is scheduled for January 27-29, 2014 at the Washington Marriott...
January 22, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Analysis of New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus

PHILADELPHIA, Jan. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21,...